Clovis Oncology Company Profile (NASDAQ:CLVS)

About Clovis Oncology

Clovis Oncology logoClovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: CLVS
  • CUSIP: 18946410
Key Metrics:
  • Previous Close: $37.44
  • 50 Day Moving Average: $24.67
  • 200 Day Moving Average: $17.64
  • 52-Week Range: $11.57 - $109.18
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -7.59
  • P/E Growth: 0.00
  • Market Cap: $1.44B
  • Outstanding Shares: 38,501,000
  • Beta: 1.98
  • Return on Equity: -130.84%
  • Return on Assets: -51.06%
  • Debt-to-Equity Ratio: 2.49%
  • Current Ratio: 5.48%
  • Quick Ratio: 5.48%
Additional Links:
Companies Related to Clovis Oncology:

Analyst Ratings

Consensus Ratings for Clovis Oncology (NASDAQ:CLVS) (?)
Ratings Breakdown: 6 Hold Ratings, 4 Buy Ratings
Consensus Rating:Hold (Score: 2.40)
Consensus Price Target: $37.30 (0.37% downside)

Analysts' Ratings History for Clovis Oncology (NASDAQ:CLVS)
DateFirmActionRatingPrice TargetDetails
9/23/2016SunTrust Banks Inc.Boost Price TargetBuy$38.00 -> $50.00View Rating Details
9/21/2016Janney Montgomery ScottDowngradeBuy -> Neutral$35.00 -> $36.00View Rating Details
9/21/2016Stifel NicolausBoost Price TargetBuy$30.00 -> $45.00View Rating Details
9/21/2016Credit Suisse Group AGUpgradeNeutral -> Outperform$19.00 -> $41.00View Rating Details
8/25/2016Piper Jaffray Cos.Reiterated RatingNeutral$14.00View Rating Details
8/24/2016MizuhoBoost Price TargetNeutral$15.00 -> $23.00View Rating Details
8/9/2016JPMorgan Chase & Co.Reiterated RatingHold$13.00View Rating Details
5/9/2016WallachBeth CapitalLower Price TargetHold$30.00 -> $22.00View Rating Details
3/28/2016Leerink SwannBoost Price TargetOutperform$104.00 -> $110.00View Rating Details
2/22/2016Goldman Sachs Group Inc.Lower Price Target$23.00 -> $19.00View Rating Details
2/23/2015Citigroup Inc.Boost Price TargetNeutral$60.00 -> $85.00View Rating Details
(Data available from 9/27/2014 forward)


Earnings History for Clovis Oncology (NASDAQ:CLVS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/8/2016Q216($2.13)($2.07)ViewListenView Earnings Details
5/5/2016Q116($2.39)($2.17)ViewListenView Earnings Details
2/25/2016Q415($2.44)($3.12)ViewListenView Earnings Details
11/5/2015Q315($2.07)($2.62)ViewListenView Earnings Details
8/6/2015Q215($1.99)($2.10)$1.17 millionViewListenView Earnings Details
5/6/2015Q115($1.82)($1.86)$13.60 millionViewListenView Earnings Details
2/25/2015Q414($1.30)($1.62)ViewListenView Earnings Details
11/6/2014Q314($1.07)($1.17)ViewListenView Earnings Details
8/7/2014Q214($0.96)($1.03)$13.60 millionViewListenView Earnings Details
5/8/2014Q114($0.85)($0.91)$13.60 millionViewListenView Earnings Details
2/27/2014Q4($0.78)($0.92)ViewListenView Earnings Details
10/31/2013Q313($0.68)($0.68)ViewListenView Earnings Details
8/1/2013Q2 2013($0.65)($0.72)ViewListenView Earnings Details
5/7/2013Q1 2013($0.60)($0.60)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)
Current Year EPS Consensus Estimate: $-9.32 EPS
Next Year EPS Consensus Estimate: $-4.93 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q3 20161($2.04)($2.04)($2.04)
Q4 20161($1.94)($1.94)($1.94)
(Data provided by Zacks Investment Research)


Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Clovis Oncology (NASDAQ:CLVS)
Insider Ownership Percentage: 17.40%
Institutional Ownership Percentage: 98.46%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/2/2015Erle T. MastCFOSell3,000$105.56$316,680.00View SEC Filing  
10/28/2015Lindsey RolfeinsiderSell4,000$98.02$392,080.00View SEC Filing  
10/15/2015Gillian C Ivers-ReadInsiderSell3,000$91.91$275,730.00View SEC Filing  
10/5/2015Lindsey RolfeinsiderSell4,000$93.04$372,160.00View SEC Filing  
10/1/2015Erle T. MastCFOSell3,000$90.22$270,660.00View SEC Filing  
9/18/2015Gillian C Ivers-ReadInsiderSell3,000$112.56$337,680.00View SEC Filing  
9/1/2015Erle T. MastCFOSell3,000$79.51$238,530.00View SEC Filing  
7/1/2015Erle T MastCFOSell3,000$85.70$257,100.00View SEC Filing  
6/1/2015Erle T MastCFOSell3,000$88.78$266,340.00View SEC Filing  
5/15/2015M James BarrettDirectorSell2,424$92.43$224,050.32View SEC Filing  
4/1/2015Erle T MastCFOSell3,000$71.25$213,750.00View SEC Filing  
3/9/2015Erle T MastCFOSell9,000$78.84$709,560.00View SEC Filing  
3/5/2015James C BlairDirectorSell8,528$77.70$662,625.60View SEC Filing  
1/16/2015Steven L HoerterInsiderSell10,000$67.00$670,000.00View SEC Filing  
12/11/2013Erle MastCFOSell50,000$52.78$2,639,000.00View SEC Filing  
12/5/2013Thorlef SpickschenDirectorSell9,000$56.10$504,900.00View SEC Filing  
6/5/2013Andrew R AllenInsiderSell22,594$68.54$1,548,592.76View SEC Filing  
6/4/2013M James BarrettDirectorSell2,483$70.80$175,796.40View SEC Filing  
6/4/2013Parters Vii L P DomainMajor ShareholderSell159,192$64.58$10,280,619.36View SEC Filing  
6/4/2013Steven L HoerterInsiderSell10,000$73.06$730,600.00View SEC Filing  
3/6/2013Parters Vii L P DomainMajor ShareholderSell250,000$24.59$6,147,500.00View SEC Filing  
8/16/2012Edward J MckinleyDirectorBuy9,701$15.50$150,365.50View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Clovis Oncology (NASDAQ:CLVS)
DateHeadline logoMoving Average Crossover Alert: Clovis Oncology (CLVS) (NASDAQ:CLVS) - September 26 at 4:31 PM logoClovis short sellers undaunted as stock price surges (NASDAQ:CLVS) - September 26 at 4:28 PM logoStocks notched another impressive showing today, with these three delivering exceptional gains (NASDAQ:CLVS) - September 23 at 3:40 PM
News Icon2 Sizzling Hot Biotechnology Stocks: Exelixis, Inc. (EXEL), Clovis Oncology, Inc. (CLVS) - The Independent Republic (NASDAQ:CLVS) - September 23 at 9:24 AM
News IconClovis Oncology Inc 20.7% Potential Upside Now Implied by Stifel (NASDAQ:CLVS) - September 22 at 4:25 PM
News IconActive biotech company shares in the news: Clovis Oncology (NASDAQ:CLVS), Halozyme Therapeutics (NASDAQ ... - The Voice Registrar (NASDAQ:CLVS) - September 22 at 9:52 AM logoCommit To Buy Clovis Oncology At $17.50, Earn 23.5% Annualized ... - Nasdaq (NASDAQ:CLVS) - September 21 at 8:19 AM logo4 Stocks To Watch: CLVS, ERII, EXEL, GIMO (NASDAQ:CLVS) - September 16 at 5:42 AM logoCan The Uptrend Continue for Clovis Oncology (CLVS)? (NASDAQ:CLVS) - September 15 at 9:41 PM
News IconAnalysts Valuations For Two Stocks: SunPower Corporation ... - The Voice Registrar (NASDAQ:CLVS) - September 15 at 4:39 PM logoClovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:CLVS) - September 14 at 8:31 AM logoIs Clovis Oncology Still a Strong Buy? (NASDAQ:CLVS) - September 12 at 12:21 PM logoClovis Oncology Inc (NASDAQ:CLVS): Worth A Billion Dollars? - Market Exclusive (NASDAQ:CLVS) - September 10 at 4:04 PM
News IconClovis Oncology Stock Jumps as FDA Skips Review Panel for New Cancer Drug (NASDAQ:CLVS) - September 10 at 8:56 AM logoClovis Oncology (CLVS) Reports FDA Doesn't Plan to Hold Advisory Committee Meeting on Rucaparib NDA (NASDAQ:CLVS) - September 10 at 8:56 AM logoWhat’s The Meaning Of The FDA Skipping Panel Review Of Clovis Oncology Inc (NASDAQ:CLVS)’s Rucaparib? (NASDAQ:CLVS) - September 10 at 8:56 AM
News IconShares Ticking Lower in Trade: Clovis Oncology, Inc. (NASDAQ:CLVS) - Post News (NASDAQ:CLVS) - September 9 at 4:09 PM logoWhat's The Meaning Of The FDA Skipping Panel Review Of Clovis ... - Market Exclusive (NASDAQ:CLVS) - September 9 at 4:09 PM logoClovis' Rucaparib Not to Face FDA Advisory Panel, Stock Up (NASDAQ:CLVS) - September 9 at 4:08 PM logoGilead Sciences: What is PARP? (NASDAQ:CLVS) - September 9 at 4:08 PM logoWhy Clovis Oncology Inc. Is Soaring Today - Motley Fool (NASDAQ:CLVS) - September 9 at 9:05 AM logoClovis Oncology (CLVS) in Focus: Stock Moves 15% Higher (NASDAQ:CLVS) - September 9 at 9:05 AM
News IconNotable Thursday Option Activity: TAP, DDD, CLVS (NASDAQ:CLVS) - September 8 at 4:09 PM logoClovis Oncology Inc. (CLVS) Has Broken Out To An 8-Month High (NASDAQ:CLVS) - September 8 at 4:09 PM logoHere's A Reason Why Clovis Oncology (CLVS) Stock Is Surging Today (NASDAQ:CLVS) - September 8 at 4:09 PM logoClovis Oncology Up As FDA Skips Review Panel For New Drug (NASDAQ:CLVS) - September 8 at 4:09 PM logoWhy Clovis Oncology Inc. Is Soaring Today (NASDAQ:CLVS) - September 8 at 1:24 PM
News IconPlacing Clovis Oncology, Inc. (NASDAQ:CLVS) Shares Under the Microscope - Post News (NASDAQ:CLVS) - September 8 at 5:13 AM logoKyle Bass Makes Huge Bet Against McDonald’s, Sells Off Clovis (NASDAQ:CLVS) - September 6 at 9:09 AM
News IconStock Gapping Down Pre-Bell: Clovis Oncology, Inc. (NASDAQ:CLVS) - Post News (NASDAQ:CLVS) - September 2 at 4:04 PM
News IconNews review of 2 biotech stocks: Clovis Oncology, Inc. (NASDAQ:CLVS), Navidea Biopharmaceuticals, Inc (NYSEMKT ... - The Voice Registrar (NASDAQ:CLVS) - September 2 at 4:04 PM
News IconAnalyst Reviews on Overbuying: Clovis Oncology Inc (NASDAQ:CLVS) - Post Registrar (NASDAQ:CLVS) - September 2 at 9:05 AM logoPfizer Inc. (NYSE:PFE) To Receive Higher Payment Than First Reported From Clovis (CLVS) (NASDAQ:CLVS) - September 1 at 11:29 AM
News IconHere’s Why Many Smart Money Investors Are Bullish on Clovis Oncology (NASDAQ:CLVS) - August 31 at 11:28 AM logoClovis Oncology (CLVS) Enters First Amended with Pfizer Over Licensing Agreement (NASDAQ:CLVS) - August 31 at 9:04 AM logoCLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:CLVS) - August 31 at 9:04 AM logoMorning Movers: Clovis Amends Pfizer Agreement; H&R Block Tumbles (NASDAQ:CLVS) - August 31 at 9:04 AM
News IconTrading the Biotech News: ImmunoCellular Therapeutics ... - The Voice Registrar (NASDAQ:CLVS) - August 29 at 4:29 PM
News IconClovis announces FDA application for accelerated approval of cancer drug (NASDAQ:CLVS) - August 25 at 4:18 PM logo5 Companies That Should Consider Kicking Their CEOs to the Curb (NASDAQ:CLVS) - August 25 at 9:13 AM logoSome strong economic data lifted stocks Tuesday, including these three (NASDAQ:CLVS) - August 24 at 4:16 PM
News IconOur Take On The Clovis Oncology Inc (CLVS) Announcement (NASDAQ:CLVS) - August 24 at 3:06 PM logoClovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U. (NASDAQ:CLVS) - August 24 at 10:40 AM
News IconClovis Oncology shares soar after FDA accepts cancer-drug application (NASDAQ:CLVS) - August 24 at 10:40 AM
News IconWhy is Clovis Oncology’s (CLVS) Stock up 27%? (NASDAQ:CLVS) - August 24 at 10:40 AM
News IconClovis Oncology Rockets as FDA Agrees to Priority Review of Rucaparib NDA (NASDAQ:CLVS) - August 24 at 10:40 AM
News IconClovis Oncology, Inc. (CLVS) Rockets on FDA Acceptance of New Drug Application (NASDAQ:CLVS) - August 24 at 10:40 AM logoHow Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again (NASDAQ:CLVS) - August 24 at 10:40 AM logoHere's a Reason Why Clovis Oncology (CLVS) Stock Climbed Today (NASDAQ:CLVS) - August 23 at 9:28 PM logoClovis shares jump as FDA grants priority review to cancer treatment (NASDAQ:CLVS) - August 23 at 9:28 PM


Clovis Oncology (NASDAQ:CLVS) Chart for Tuesday, September, 27, 2016

Last Updated on 9/27/2016 by Staff